Twist Bioscience Corp
For the period ended Sep 30, 2024. Filed Nov 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 18, 2024
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year ended September 30, | |||
|---|---|---|---|
| (in thousands) | 2024 | 2023 | 2022 |
| Cash flows from operating activities | |||
| Net loss | $(208,726) | $(204,618) | $(217,863) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation and amortization | 31,432 | 29,310 | 16,514 |
| Impairment of long-lived assets | 44,930 | 6,785 | — |
| Non-cash lease expense, net of tenant improvement allowance | 940 | 2,573 | 20,127 |
| Stock-based compensation | 50,925 | 30,278 | 79,664 |
| Change in fair value of contingent considerations and holdbacks | — | (5,913) | (14,245) |
| Gain on deconsolidation of Revelar | — | — | (4,607) |
| Other non-cash adjustments | 994 | 120 | 1,381 |
| Changes in assets and liabilities: | |||
| Accounts receivable, net | 8,444 | (4,320) | (9,622) |
| Inventories | 7,986 | 7,238 | (7,536) |
| Prepaid expenses and other current assets | 382 | (4,166) | (2,551) |
| Other non-current assets | 431 | 1,376 | 7,273 |
| Accounts payable | (11,805) | (2,508) | 7,383 |
| Accrued expenses | 4,415 | 2,578 | 2,269 |
| Accrued compensation | 7,875 | (1,099) | 4,852 |
| Other liabilities | (2,317) | (108) | (7,424) |
| Net cash used in operating activities | $(64,094) | $(142,474) | $(124,385) |
| Cash flows from investing activities | |||
| Purchases of property and equipment | $(5,076) | $(27,779) | $(101,857) |
| Business acquisition, net of cash acquired | — | — | (8,160) |
| Deconsolidation of cash and cash equivalent relating to Revelar | — | — | (5,755) |
| Purchases of investments | (51,905) | (76,345) | (217,639) |
| Proceeds from maturity of investments | 53,910 | 154,736 | 100,481 |
| Net cash provided by (used in) investing activities | (3,071) | 50,612 | (232,930) |
| Cash flows from financing activities | |||
| Proceeds from exercise of stock options | $7,100 | $1,379 | $6,014 |
| Proceeds from public offerings, net of underwriting discounts, commissions and offering expenses | — | — | 269,822 |
| Proceeds from issuance under employee stock purchase plan | 3,765 | 3,937 | 4,010 |
| Repayments of long-term debt | — | — | (1,558) |
| Repurchases of common stock for income tax withholding | (3,975) | (4,405) | (7,754) |
| Net cash provided by financing activities | $6,890 | $911 | $270,534 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | $126 | $(27) | $(319) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (60,149) | (90,978) | (87,100) |
| Cash, cash equivalents, and restricted cash at beginning of year | 289,281 | 380,259 | 467,359 |
| Cash, cash equivalents, and restricted cash at end of year | $229,132 | $289,281 | $380,259 |
| Supplemental disclosure of cash flow information | |||
| Interest paid | $— | $— | $9 |
| Income taxes paid, net of refunds | 344 | 420 | 246 |
| Non-cash investing and financing activities | |||
| Property and equipment additions included in accrued expenses and accounts payable | $92 | $772 | $6,297 |
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | — | 6,676 | 21,367 |
| Issuance of common stock in connection with the business acquisition | — | 5,860 | 77,122 |
| Tenant improvement allowance capitalized in property and equipment | 2,719 | — | — |
| Conversion of convertible notes | — | 3,711 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.